Journal
PHARMACEUTICAL RESEARCH
Volume 29, Issue 9, Pages 2543-2554Publisher
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s11095-012-0785-6
Keywords
intestinal permeation enhancers; nasal permeation enhancers; oral peptide permeation; paracellular fluxes; Ussing chambers
Funding
- Science Foundation Ireland [07/SRC B1144]
- Critical Pharmaceuticals (UK)
- UCD Ad Astra Scholarship
- Science Foundation Ireland (SFI) [07/SRC/B1144] Funding Source: Science Foundation Ireland (SFI)
Ask authors/readers for more resources
CriticalSorb (TM) is a novel absorption enhancer based on Solutol(A (R)) HS15, one that has been found to enhance the nasal transport. It is in clinical trials for nasal delivery of human growth hormone. The hypothesis was that permeating enhancement effects of the Solutol(A (R))HS15 component would translate to the intestine. Rat colonic mucosae were mounted in Ussing chambers and Papp values of [C-14]-mannitol, [C-14]-antipyrine, FITC-dextran 4000 (FD-4), and TEER values were calculated in the presence of CriticalSorb (TM). Tissues were fixed for H & E staining. Caco-2 monolayers were grown on Transwells (TM) for similar experiments. CriticalSorb (TM)(0.01% v/v) significantly increased the Papp of [C-14]-mannitol, FD-4 [C-14]-antipyrine across ileal and colonic mucosae, accompanied by a decrease in TEER. In Caco-2 monolayers, it also increased the Papp of [C-14]-mannitol FD-4 and [C-14]-antipyrine over 120 min. In both monolayers and tissues, it acted as a moderately effective P-glycoprotein inhibitor. There was no evidence of cytotoxicity in Caco-2 at concentrations of 0.01% for up to 24 h and histology of tissues showed intact epithelia at 120 min. Solutol(A (R)) HS15 is the key component in CriticalSorb (TM) that enables non-cytotoxic in vitro intestinal permeation and its mechanism of action is a combination of increased paracellular and transcellular flux.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available